Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for a tumor-associated antigen (TAA) and at least one binding site for an antigen expressed on an effector T cell, NK cell, monocyte or neutrophil. The bispecific antibodies are of use for inducing an immune response against a TAA-expressing tumor. The methods may comprising administering the bispecific antibody in combination with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC. In preferred embodiments, the checkpoint inhibitor is a chimeric or humanized anti-PD1 antibody as described herein.
IBC Pharmaceuticals, Inc.
C C C A C C A C A C C C A A A A C A C A C A C A A C C A A C A
C07K C07K C07K A61K C07K C07K A61K C07K A61K C07K C07K C07K A61K A61K A61K A61K C07K A61K C07K A61K C07K A61K C07K A61K A61K C07K C07K A61K A61K C07K A61K
additional additional inventional inventional inventional inventional inventional inventional inventional additional additional inventional inventional inventional additional inventional inventional inventional inventional additional additional inventional additional inventional inventional inventional additional additional inventional inventional inventional
David M. Chien-Hsing Edmund A.
Goldenberg Chang Rossi